Stereochemistry | ABSOLUTE |
Molecular Formula | C22H27N9O7S2 |
Molecular Weight | 593.636 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SCC(CN3N=NC(C)=N3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C4=CSC(N)=N4)C(=O)OCOC(=O)C(C)(C)C
InChI
InChIKey=UIYAXIPXULMHAI-JLGRZTKVSA-N
InChI=1S/C22H27N9O7S2/c1-10-26-29-30(27-10)6-11-7-39-18-14(25-16(32)13(28-36-5)12-8-40-21(23)24-12)17(33)31(18)15(11)19(34)37-9-38-20(35)22(2,3)4/h8,14,18H,6-7,9H2,1-5H3,(H2,23,24)(H,25,32)/b28-13-/t14-,18-/m1/s1
Cefteram is a semisynthetic cephalosporin formulated for oral administration as the prodrug ester, cefteram pivoxil. The mechanism of action of cefteram is inhibition of bacterial cell wall synthesis. Cefteram exerts its bactericidal activity by strongly binding to penicillin-binding protein (PBP) 3, 1A, and 1Bs. The drug is available in Japan and is used for the treatment of bacterial infections.
Originator
Approval Year
PubMed
Patents
Sample Use Guides
The usual adult dosage for oral use is 150 − 600 mg (potency) of cefteram pivoxil daily in 3 divided doses after meals.
Route of Administration:
Oral
The activity of cefteram was compared with that of other P-lactams against a total of 491 bacterial strains. The drug was highly active (MIC for 90% of the strains tested [MIC90] < 2 ug/ml) against the majority of the members of the family Enterobacteriaceae, Haemophilus influenzae, Neisseria spp., and Streptococcuspneumoniae, being at least 16-fold more active than cephalexin and 8-fold more active than cefuroxime. There was no activity against Pseudomonas aeruginosa, Enterobacter sp., and Citrobacter sp. Staphylococcus aureus was moderately susceptible to cefteram (MIC90, 8 ug/ml).